Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · CorMedix Inc. (CRMD)

CorMedix: FDA accepts REZZAYO sNDA for prophylaxis with Priority Review, PDUFA date Q1 2027

Neutral Impact 3 of 5 legal/regulatory Written later

The FDA accepted for filing a supplemental New Drug Application for REZZAYO (rezafungin) for the prophylaxis of invasive fungal disease and granted Priority Review, with a PDUFA target action date in Q1 2027. The application was submitted by partner Mundipharma and is supported by the Phase III ReSPECT study. Acceptance does not assure approval, and CorMedix is targeting promotional efforts beginning in H2 2027 if the indication is approved.

Key points

  • FDA accepted the sNDA for filing and granted Priority Review
  • PDUFA target action date is in Q1 2027
  • Application was submitted by Mundipharma, CorMedix's global development partner
  • If approved, CorMedix is targeting promotional efforts beginning in H2 2027

The filing

CompanyCorMedix Inc. (CRMD)
Form8-K, current report
Filed with the SECOct 19, 2026, 8:00 AM ET
Accession number0001213900-26-110477

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 19, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.